$SGMO News
Last published 5mo ago
- 5mo agoHIVEIOVANWBOOTLC+1How Advanced Drug Delivery Could Improve Existing Cancer TreatmentsGlobeNewswireAUSTIN, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are
- 6mo agoSGMOSangamo Therapeutics Announces First Quarter 2026 Earnings CallGlobeNewswireRICHMOND, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (OTCQB Venture Market: SGMO), a genomic medicine company today announced that the company has scheduled the release of its first quarter
- 6mo agoSGMOSangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)GlobeNewswireRICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three
- 6mo agoSGMOSangamo Therapeutics Announces Transition to Trading on OTCQB Venture MarketGlobeNewswireRICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Nasdaq Capital Market
- 7mo agoSGMOSangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial ResultsGlobeNewswireAnnounced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in
- 8mo agoSGMOSangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseGlobeNewswireData support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment
- 9mo agoSGMOSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026GlobeNewswireData support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment
- 9mo agoSGMOSangamo Therapeutics Announces Pricing of $25.0 Million Underwritten OfferingGlobeNewswireRICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its
- 10mo agoSGMOSangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry DiseaseGlobeNewswireSTAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve
- 11mo agoSGMOSangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber NeuropathyGlobeNewswireRICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track
- 11mo agoSGMOSangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry DiseaseGlobeNewswireRICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted Sangamo's request
- 1y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial ResultsGlobeNewswireHeld meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support accelerated
- 1y agoSGMOSangamo Therapeutics Announces Third Quarter 2025 Earnings CallGlobeNewswireRICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter 2025 financial
- 1y agoSGMOSangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at International Congress of Inborn Errors of Metabolism 2025GlobeNewswireTotality of data supports potential for isaralgagene civaparvovec as a one-time, durable treatment of the underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current
- 1y agoSGMOSangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial ResultsGlobeNewswireAnnounced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the
- 1y agoSGMOSangamo Therapeutics Announces Second Quarter 2025 Earnings CallGlobeNewswireRICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial
- 1y agoSGMOSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseBusiness WireSTAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve
- 1y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsBusiness WireAnnounced capsid license agreement with Lilly to deliver genomic medicines for up to five central nervous system (CNS) disease targets. Received $18 million upfront license fee for first target and eligible to earn up
- 1y agoSGMOSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 12,235,000 shares of its common stock and pre-funded warrants to purchase
- 1y agoSGMOSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m.
- 1y agoSGMOSangamo Therapeutics Announces First Quarter 2025 Earnings CallBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the company has scheduled the release of its first quarter 2025 financial results after the markets close on Monday, May 12,
- 1y agoSGMOSangamo Therapeutics Announces Important Derisking Milestones in Pathway to Anticipated BLA Submission for ST-920 in Fabry DiseaseBusiness WireAll dosed patients have passed one-year milestone required by U.S. Food and Drug Administration (FDA) for Accelerated Approval regulatory pathway for ST-920. According to preliminary analysis, mean estimated
- 1y agoSGMOSangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Business WireOne abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal
- 1y agoSGMOSangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous SystemBusiness WireAgreement grants Lilly rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is eligible to earn up to $1.4
- 1y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireContinued to advance our prioritized neurology genomic medicine pipeline towards the clinic. Announced two neurology license agreements with blue-chip pharma companies, including a global epigenetic regulation and
- 1y agoSGMOSangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor ConferenceBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quarter and full year 2024 financial results after the markets close on
- 1y agoSGMOSangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety ProfileBusiness WireSustained benefit demonstrated with elevated expression of alpha-galactosidase A (α-Gal A) activity maintained for nearly four years for the longest treated patient as of the data cutoff date Positive mean estimated
- 1y agoSGMOSangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer's Decision to Cease Development of Giroctocogene FitelparvovecBusiness Wire- Based on positive results from Phase 3 AFFINE trial, which met primary and secondary endpoints, Sangamo plans to explore all options to commercialize the asset, including seeking a potential new collaboration
- 1y agoSGMOTYO:4503Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesBusiness Wire- Agreement grants Astellas rights to employ Sangamo's novel proprietary capsid, STAC-BBB, for up to five potential neurological disease targets - Sangamo to receive a $20 million upfront license fee and is eligible
- 1y agoSGMOAstellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological DiseasesPR NewswireAstellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine...
- 1y agoSGMOSangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic PainBusiness WireSangamo plans to initiate enrollment of patients in the Phase 1/2 study for ST-503 in mid-2025 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the U.S. Food and Drug
- 2y agoSGMOSangamo Therapeutics, Inc. (SGMO) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial ResultsBusiness WireAnnounced clear regulatory pathway to Accelerated Approval from U.S. Food and Drug Administration (FDA) for isaralgagene civaparvovec in Fabry disease, using data from ongoing Phase 1/2 STAAR study, avoiding requirement
- 2y agoSGMOSangamo Therapeutics Announces Third Quarter 2024 Conference Call and WebcastBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its third quarter 2024 financial results after the market close on Tuesday, November
- 2y agoSGMOSangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025Business Wire- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional
- 2y agoSGMOSangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial ResultsBusiness WireAnnounced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license
- 2y agoSGMOSangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative DiseasesBusiness WireAgreement leverages Sangamo's proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases Sangamo expected to receive $50 million in near-term upfront
- 2y agoSGMOSangamo Therapeutics Announces Second Quarter 2024 Conference Call and WebcastBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6,
- 2y agoSGMOPFEBMRNPfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trialCNBCThe hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
- 2y agoSGMOSangamo Therapeutics Reports on Pfizer's Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy CandidateBusiness WireGiroctocogene fitelparvovec trial meets primary and key secondary objectives of superiority compared to prophylaxis Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today reported on Pfizer Inc.'s
- 2y agoSGMOSangamo Therapeutics, Inc. (SGMO) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial ResultsBusiness WireShowcased 20 presentations at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting demonstrating progression of neurology-focused preclinical pipeline, including additional data from novel
- 2y agoSGMOSangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome EditingBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
- 2y agoSGMOSangamo Therapeutics Announces First Quarter 2024 Conference Call and WebcastBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9,
- 2y agoSGMOSangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)Business WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 Sangamo abstracts for presentation at the 27th ASGCT
- 2y agoSGMOSangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingBusiness WireSangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that it has entered into a securities purchase agreement with institutional investors, providing for the purchase and sale of an
- 2y agoSGMOSangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsBusiness WireData from novel proprietary neurotropic adeno-associated virus (AAV) delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier (BBB) penetration in non-human primates (NHPs) following intravenous
- 2y agoSGMOSangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPsBusiness WireNovel AAV capsid engineered by Sangamo showed robust penetration of blood-brain barrier (BBB) and widespread transgene expression throughout brain in non-human primates (NHPs) following intravenous